Analyst Reco. Ultragenyx Pharmaceutical Inc.

Equities

RARE

US90400D1081

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
44.28 ^USD	-1.84%		+4.66%	-7.40%

Apr. 22	RBC Starts Ultragenyx Pharmaceutical at Outperform, Speculative Risk With $77 Price Target, Sees 'Particularly Attractive' Risk/Reward	MT
Apr. 15	Health Care Ticks Down Amid Rotation From Rate-Sensitive Sectors -- Health Care Roundup	DJ

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RBC Starts Ultragenyx Pharmaceutical at Outperform, Speculative Risk With $77 Price Target, Sees 'Particularly Attractive' Risk/Reward	Apr. 22	MT
JPMorgan Adjusts Price Target on Ultragenyx Pharmaceutical to $92 From $88, Maintains Overweight Rating	Mar. 18	MT
Canaccord Genuity Adjusts Ultragenyx Pharmaceutical's Price Target to $111 From $110, Keeps Buy Rating	Feb. 21	MT
Wedbush Lifts Ultragenyx Pharmaceutical's PT to $48 From $47, Notes Fuller Catalyst Lineup for 2024; Keeps Neutral Rating	Feb. 16	MT
Wedbush Raises Ultragenyx Pharmaceutical's PT to $47 From $43, Updates Model After Pre-Announced Full-Year 2023 Figures, Increases Forward Trajectory on Crysvita; Maintains Neutral Rating	Jan. 08	MT
Wells Fargo Initiates Ultragenyx Pharmaceutical With Overweight Rating, Price Target is $72	Dec. 08	MT
JPMorgan Adjusts Ultragenyx Pharmaceutical Price Target to $74 From $76, Maintains Overweight Rating	Nov. 24	MT
Morgan Stanley Adjusts Price Target on Ultragenyx Pharmaceutical to $84 From $90, Maintains Overweight Rating	Nov. 03	MT
Wedbush Cuts Price Target on Ultragenyx Pharmaceutical to $43 From $47, Maintains Neutral Rating	23-10-17	MT
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)	23-10-14	CI
Morgan Stanley Cuts Ultragenyx Pharmaceutical's Price Target to $90 From $95, Keeps Overweight Rating	23-10-10	MT
Wedbush Trims Ultragenyx Pharmaceutical's PT to $47 From $49, Keeps Neutral Rating	23-08-04	MT
Citigroup Adjusts Ultragenyx Pharmaceutical Price Target to $133 From $130, Maintains Buy Rating	23-06-06	MT
Evercore ISI Upgrades Ultragenyx Pharmaceutical to Outperform From In Line, Raises Price Target to $80 From $60	23-06-06	MT
Wedbush Raises Ultragenyx Pharmaceutical's Price Target to $51 From $48, Keeps Neutral Rating	23-06-06	MT
Wedbush Lifts Ultragenyx Pharmaceutical's Price Target to $48 From $47, Keeps Neutral Rating	23-05-08	MT
Cantor Fitzgerald Initiates Ultragenyx Pharmaceutical at Overweight With $114 Price Target	23-04-26	MT
Baird Adjusts Price Target on Ultragenyx Pharmaceutical to $57 From $50, Maintains Outperform Rating	23-02-17	MT
Wedbush Trims Price Target on Ultragenyx Pharmaceutical to $47 From $48, Maintains Neutral Rating	23-02-17	MT
Canaccord Genuity Assumes Coverage on Ultragenyx Pharmaceutical With Buy Rating, $90 Price Target	23-01-18	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Ultragenyx Pharmaceutical Inc.

Equities

RARE

US90400D1081

Analyst Reco.

Filters